Neuroene Therapeutics is organized around development of new therapeutics for difficult-to-treat neurological diseases: epilepsy, Parkinson and Mitochhrondrial disease. Anchored in collaborative research between Medical University of South Carolina and the firm's principals, the firm is working on a novel Vitamin K based therapeutics that target new mechanisms and are safe, specific, and different to current drugs on the market for the trageted diseases noted. Himan body organs need an active form of Vitamin K in order to be healthy. However, the form of Vitamin K that is obtained from a person's diet needs to be further processed, to produce the active form for the proper function and health of the organ. The modified form of Vitamin K which Neuroene principals are developing doesnt need to be processed because it is a direct substitute for the active form that goes directly to the organ where it is needed.
